Royalty Report: Drugs, Diagnostic, Biotechnology – Collection: 1464


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 6


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6

Primary Industries

  • Drugs
  • Diagnostic
  • Biotechnology
  • Disease
  • Diagnostic Substances
  • Antibody
  • Assay
  • Cancer
  • Immune

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 1464

License Grant
The Company entered into an exclusive license agreement with a Japanese pharmaceutical company, for the manufacturing right to an antibody used in test kits for cardiovascular risk; the antibody measures fibrinogen, a significant risk factor for coronary artery disease; diagnostic assays that contain the Company’s monoclonal antibody, 45-J.
License Property
The antibody will be included in automated blood test systems and administered along with routine blood tests.

IPSCIO Record ID: 26530

License Grant
The Company signed a license agreement with the University for the exclusive rights of Mammastatin technology.
License Property
Mammastatin is a protein that has been found to be present in relatively higher levels in the breast tissue of healthy women as compared to those women that eventually have developed breast cancer.
Field of Use
The Comany developed the MSA test as a simple blood serum diagnostic that could measure the quantity of Mammastatin in blood serum using monoclonal antibody technology, whereby the results from that test could then be used to assess women’s risk of developing breast cancer.

IPSCIO Record ID: 26919

License Grant
The Company has taken a license to two U.S. patents, which expire in the financial years 2004 and 2014 respectively, covering the format of Uni-Gold(TM) rapid test device i.e. the visual result given by its one step strip test.
License Property
The Company 's Uni-Gold one step assays detect antibodies to various infectious diseases and conditions in serum and plasma or whole blood based on the principle of an immuno-chromatographic assay.  The Company currently markets four products based on this technology, Uni-Gold HIV, Uni-Gold Hepatitis B, Uni-Gold hCG (pregnancy) and Uni-Gold H. pylori.

IPSCIO Record ID: 163133

License Grant
Licensor grants a Sublicense to Licensee and its Affiliates, to use the Licensor Antibodies, Cell Lines and Derivatives for the purpose of making, having made, using, selling and having sold Licensee Products.  Licensor shall provide Licensee quantities of Licensor Antibodies or Cell Lines and Derivatives, and information relating thereto.  Licensor agrees to deliver additional viable aliquots of Cell Lines or Derivatives to replace any aliquots previously delivered, which have subsequently become incapable of producing Licensor Monoclonal Antibodies and which are the same as the Licensor Cell Lines or Derivatives previously received by Licensee.

In order to protect Licensees source of supply of the Cell Lines or Derivatives Licensor warrants and agrees that Licensor shall maintain the Cell Lines and Derivatives in such a manner as will best preserve the viability thereof, in accordance with established scientific procedures.

License Property
Licensor holds exclusive licenses with respect to the Antibodies. Licensor is a supplier of specialty reagents, immuno-assay test kits and molecular research products to customers involved in biomedical research, the biotechnology industry and pharmaceutical drug discovery.

Monoclonal Antibodies to Human Interferongamma
        *1.       Antibody B133.5

         2.       Antibody 3C11C8

         3.       Antibody 2G1

Monoclonal Antibodies to Human Granulocyte Marophage-Colony Stimulating Factor

         1.       Antibody 3092

         2.       Antibody 3034

         3.       Antibody 1089

         4.       Antibody 4117

         5.       Antibody 2118

         6.       Antibody 1028

Monoclonal Antibodies to Human Tumor Necrosis Factor-alpha

         *1.      Antibody B154.7.1

         *2.      Antibody B154.9.1

Field of Use
The purpose for this agreement is for research use.

IPSCIO Record ID: 4026

License Grant
The Licensor, an individual, hereby grants to the Licensee an exclusive License, within the worldwide territory, except Japan, to utilize the Technology to develop, manufacture, use, promote to sell, and sell any Products during the term of this License Agreement. The Licensee shall not subLicense such rights to any third parties without prior written consent of the Licensor.
License Property
The Licensor is willing to grant access to all information in his possession regarding methods for the determination of oxidized lipoproteins and access to all related analytes, antibodies and antigens, existing as of the date of this License Agreement and any and all improvements or future developments related thereto, including those related to the Patents or the Japanese Patents to develop any human diagnostic products to be manufactured and sold by Corgenix, including those that include the Patents or the Japanese Patents.

Licensed Patents
5,900,359; 7,160,733; 7,422,864; 7,455,976; 1 548 436; 04713170
Japanese Patents 07-510213; PCT/JP02/00723; 2002-261366

Field of Use
The exclusive rights granted relates to the methods to determine oxidized lipoproteins and related analytes, antibodies and antigens.

IPSCIO Record ID: 211874

License Grant
Licensor grants to the Australian Licensee a non-transferable, non-exclusive, perpetual and irrevocable license under the Patent to make, have made, use, sell, offer to sell, and import canine heartworm test kit products (CHW Kits) that contain the anti-CHW monoclonal antibody from clone key DI 16 872.5 (the CHW Antibody) or any derivatives thereof created or developed by or for Licensee (the CHW Antibody Derivatives).

Licensor further grants a non-transferable, non-exclusive, perpetual and irrevocable license under the Patent to use, sell, offer to sell, and import CHW Antibody contained in CHW Kits; and, CHW Antibody Derivatives contained in CHW Kits.

Licensee shall have no right to sublicense.

Licensor grants Licensee an immunity from suit for licensed products.

Licensor grants an exclusive, non-transferable, sublicensable (only to Licensee partners) license, to use and display  Japan Witness® trademark only for ICT lateral flow veterinary test kit products sold in Japan. With regard to this license, Licensee shall not, and shall have no right to, sell outside of Japan, or authorize its distributors, resellers, and OEMs to sell outside of Japan, ICT lateral flow veterinary test kit products bearing Japan Witness® trademark.

License Property
The patent is for Immunoassay for Anti-Dirofilaria Immitis Antibody.  

The biological materials are Anti-CHW MAb, clone key DI16872.5-USDA code E118.00, Rabbit Anti-CHW PAb-USDA code E019.00, Rabbit Anti-CPV PAb-USDA code E024.01, and, Anti-CPV MAb, clone key A1C2.32-USDA code E024.01.

The products are canine heartworm test kits.

Field of Use
Licensee is in the business of developing, manufacturing and marketing veterinary diagnostics and other animal health related products worldwide, including ICT lateral flow veterinary test kit products which, for purposes of this Agreement, shall mean all veterinary diagnostic products in ICT (immunochromatography strip assay) format.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.